We are analyzing https://link.springer.com/article/10.1007/s12032-025-02783-5.

Title:
Revolutionising cancer intervention: the repercussions of CAR-T cell therapy on modern oncology practices | Medical Oncology
Description:
Chimeric Antigen Receptor T-cell (CAR-T) therapy represents a groundbreaking advance in oncology, leveraging patient-specific immune cells to target malignant tumours precisely. By equipping T cells with synthetic receptors, CAR-T therapy achieves remarkable antitumor effects and offers hope for durable cancer control. However, several limitations persist, including antigen scarcity, immunosuppressive tumour microenvironments, and T-cell exhaustion. CRISPR-Cas9 gene editing has enhanced CAR-T potency by knocking out immune checkpoints (PD-1, CTLA-4) and improving persistence, while RNA interference (RNAi) silences immune-evasion genes (e.g. SOCS1). Nanozyme-based delivery systems enable precise CRISPR-Cas9 delivery (> 70% editing efficiency) and tumour targeting, overcoming instability and off-target effects. Innovations like SUPRA CARs, armoured CAR-T cells (e.g. IL-12/IL-21-secreting TRUCKs), and dual checkpoint inhibition synergize to reprogram the tumour microenvironment, reducing relapse by 40% in trials. Despite progress, high costs, manufacturing hurdles, and ethical concerns (e.g. germline editing risks) remain critical barriers. Emerging solutions include universal off-the-shelf CAR-Ts, hybrid nano-CRISPR systems, and AI-driven design, paving the way for scalable, personalised immunotherapy. This review highlights breakthroughs in CRISPR, RNAi, and nanotechnology, underscoring CAR-T therapy’s transformative potential while addressing translational challenges for broader clinical adoption.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,643,328 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

pubmed, google, scholar, cas, cancer, central, cells, cell, cart, therapy, car, zhang, crisprcas, wang, article, chimeric, antigen, tumor, liu, tcell, editing, immunotherapy, sci, res, receptor, targeting, nat, clinical, mol, tumors, oncol, immunol, chen, yang, med, tang, gene, phase, solid, human, nature, oncology, rev, clin, genome, data, research, antitumor, tumour, delivery,

Topics {✒️}

activating hif-1α/β-catenin/vegf signaling microhomology-mediated end-joining-dependent integration crispr/cas9-mediated genome engineering genome-scale crispr-cas9 knockout high-fidelity crispr–cas9 nucleases kte-c19 anti-cd19 car cas9-mediated gene disruption crispr/cas9-mediated knockout crispr/cas9-mediated mutagenesis crispr-cas9 gene editing crispr-cas9 genome editing crispr/cas9 genome editing hybrid nano-crispr systems najeeb ullah khan chimeric antigen receptor–modified chimeric antigen receptor-modified il-12/il-21-secreting trucks t-cell antigen receptor neo-antigen-based immunotherapy caf-mediated emt regulation il-21/il-21r regulates dendritic cell-derived osteopontin mesothelin-positive solid tumors double-strand breaks induced rna-guided cas9 nucleases crispr-cas9 disruption revolutionising cancer intervention adoptively transferred antigen-specific month download article/chapter triple-negative breast cancer car-t-cell therapy cell anti-tumor immunity crispr-engineered car19 universal germ-line gene therapy anti-solid tumor efficacy large b-cell lymphoma myxoma virus-infected car silences immune-evasion genes promotes therapeutic resistance dual checkpoint inhibition synergize drug-loaded nanoprobes improve mol therapy-nucleic acids therapy crispr-cas9 chimeric antigen receptor chimeric antigen receptor modern oncology practices generation cd19-specific car crispr/cas9 application crispr–cas9 leads emerging solutions include universal

Questions {❓}

The challenges of medical ethics in China: are gene-edited babies enough?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Revolutionising cancer intervention: the repercussions of CAR-T cell therapy on modern oncology practices
         description:Chimeric Antigen Receptor T-cell (CAR-T) therapy represents a groundbreaking advance in oncology, leveraging patient-specific immune cells to target malignant tumours precisely. By equipping T cells with synthetic receptors, CAR-T therapy achieves remarkable antitumor effects and offers hope for durable cancer control. However, several limitations persist, including antigen scarcity, immunosuppressive tumour microenvironments, and T-cell exhaustion. CRISPR-Cas9 gene editing has enhanced CAR-T potency by knocking out immune checkpoints (PD-1, CTLA-4) and improving persistence, while RNA interference (RNAi) silences immune-evasion genes (e.g. SOCS1). Nanozyme-based delivery systems enable precise CRISPR-Cas9 delivery (> 70% editing efficiency) and tumour targeting, overcoming instability and off-target effects. Innovations like SUPRA CARs, armoured CAR-T cells (e.g. IL-12/IL-21-secreting TRUCKs), and dual checkpoint inhibition synergize to reprogram the tumour microenvironment, reducing relapse by 40% in trials. Despite progress, high costs, manufacturing hurdles, and ethical concerns (e.g. germline editing risks) remain critical barriers. Emerging solutions include universal off-the-shelf CAR-Ts, hybrid nano-CRISPR systems, and AI-driven design, paving the way for scalable, personalised immunotherapy. This review highlights breakthroughs in CRISPR, RNAi, and nanotechnology, underscoring CAR-T therapy’s transformative potential while addressing translational challenges for broader clinical adoption.
         datePublished:2025-05-31T00:00:00Z
         dateModified:2025-05-31T00:00:00Z
         pageStart:1
         pageEnd:18
         sameAs:https://doi.org/10.1007/s12032-025-02783-5
         keywords:
            CAR-T therapy
            CRISPR-Cas9 in oncology
            Cancer immunotherapy
            Tumour microenvironment
            Genetic engineering
            Nanozymes in cancer
            Oncology
            Hematology
            Pathology
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-025-02783-5/MediaObjects/12032_2025_2783_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-025-02783-5/MediaObjects/12032_2025_2783_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-025-02783-5/MediaObjects/12032_2025_2783_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-025-02783-5/MediaObjects/12032_2025_2783_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-025-02783-5/MediaObjects/12032_2025_2783_Fig5_HTML.png
         isPartOf:
            name:Medical Oncology
            issn:
               1559-131X
            volumeNumber:42
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Hossam Kamli
               affiliation:
                     name:King Khalid University
                     address:
                        name:Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Najeeb Ullah Khan
               affiliation:
                     name:The University of Agriculture
                     address:
                        name:Institute of Biotechnology and Genetic Engineering, The University of Agriculture, Peshawar, Pakistan
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Revolutionising cancer intervention: the repercussions of CAR-T cell therapy on modern oncology practices
      description:Chimeric Antigen Receptor T-cell (CAR-T) therapy represents a groundbreaking advance in oncology, leveraging patient-specific immune cells to target malignant tumours precisely. By equipping T cells with synthetic receptors, CAR-T therapy achieves remarkable antitumor effects and offers hope for durable cancer control. However, several limitations persist, including antigen scarcity, immunosuppressive tumour microenvironments, and T-cell exhaustion. CRISPR-Cas9 gene editing has enhanced CAR-T potency by knocking out immune checkpoints (PD-1, CTLA-4) and improving persistence, while RNA interference (RNAi) silences immune-evasion genes (e.g. SOCS1). Nanozyme-based delivery systems enable precise CRISPR-Cas9 delivery (> 70% editing efficiency) and tumour targeting, overcoming instability and off-target effects. Innovations like SUPRA CARs, armoured CAR-T cells (e.g. IL-12/IL-21-secreting TRUCKs), and dual checkpoint inhibition synergize to reprogram the tumour microenvironment, reducing relapse by 40% in trials. Despite progress, high costs, manufacturing hurdles, and ethical concerns (e.g. germline editing risks) remain critical barriers. Emerging solutions include universal off-the-shelf CAR-Ts, hybrid nano-CRISPR systems, and AI-driven design, paving the way for scalable, personalised immunotherapy. This review highlights breakthroughs in CRISPR, RNAi, and nanotechnology, underscoring CAR-T therapy’s transformative potential while addressing translational challenges for broader clinical adoption.
      datePublished:2025-05-31T00:00:00Z
      dateModified:2025-05-31T00:00:00Z
      pageStart:1
      pageEnd:18
      sameAs:https://doi.org/10.1007/s12032-025-02783-5
      keywords:
         CAR-T therapy
         CRISPR-Cas9 in oncology
         Cancer immunotherapy
         Tumour microenvironment
         Genetic engineering
         Nanozymes in cancer
         Oncology
         Hematology
         Pathology
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-025-02783-5/MediaObjects/12032_2025_2783_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-025-02783-5/MediaObjects/12032_2025_2783_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-025-02783-5/MediaObjects/12032_2025_2783_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-025-02783-5/MediaObjects/12032_2025_2783_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-025-02783-5/MediaObjects/12032_2025_2783_Fig5_HTML.png
      isPartOf:
         name:Medical Oncology
         issn:
            1559-131X
         volumeNumber:42
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Hossam Kamli
            affiliation:
                  name:King Khalid University
                  address:
                     name:Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Najeeb Ullah Khan
            affiliation:
                  name:The University of Agriculture
                  address:
                     name:Institute of Biotechnology and Genetic Engineering, The University of Agriculture, Peshawar, Pakistan
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Medical Oncology
      issn:
         1559-131X
      volumeNumber:42
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:King Khalid University
      address:
         name:Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia
         type:PostalAddress
      name:The University of Agriculture
      address:
         name:Institute of Biotechnology and Genetic Engineering, The University of Agriculture, Peshawar, Pakistan
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Hossam Kamli
      affiliation:
            name:King Khalid University
            address:
               name:Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia
               type:PostalAddress
            type:Organization
      name:Najeeb Ullah Khan
      affiliation:
            name:The University of Agriculture
            address:
               name:Institute of Biotechnology and Genetic Engineering, The University of Agriculture, Peshawar, Pakistan
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia
      name:Institute of Biotechnology and Genetic Engineering, The University of Agriculture, Peshawar, Pakistan
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(296)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.3s.

LINK . SPRINGER . COM {}